CEBPA-DT: A Potential Drug Target and Biomarker (G80054)

Target Name: CEBPA-DT

NCBI ID: G80054

CEBPA-DT

Other Name(s): FLJ12355 | CEBPA-AS1 | CEBPA divergent transcript | ADINR

CEBPA-DT: A Potential Drug Target and Biomarker

Abstract:

CEBPA-DT (Ceramide Esterase B, Plasminogen-Activated Lysine Endothelial Blockers), a novel protein expressed in endothelial cells, has been identified as a potential drug target and biomarker for various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders. This article reviews the current literature on CEBPA-DT, including its expression, function, and potential therapeutic applications.

Introduction:

Ceramide Esterase B (CEBPA) is a highly conserved protein that is expressed in various cell types, including endothelial cells. It plays a critical role in the regulation of cell signaling pathways, including the TGF-β pathway. CEBPA has been shown to be involved in various physiological processes, including cell adhesion, migration, and angiogenesis. In addition, CEBPA has also been implicated in the development and progression of various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders.

Plasminogen-Activated Lysine Endothelial Blockers (PALs) are a subclass of CEBPA that have been shown to promote endothelial cell proliferation and migration. These blockers are derived from CEBPA by the removal of its lysine tail, which has been shown to be involved in the regulation of cell signaling pathways. PALs have been shown to be involved in various physiological processes, including vascular remodeling, angiogenesis, and cancer progression.

CEBPA-DT: A Potential Drug Target:

The expression and function of CEBPA and its PAL subclasses have been extensively studied in various cell types, including endothelial cells. Several studies have shown that CEBPA and its PAL subclasses are expressed in endothelial cells and are involved in various physiological processes, including cell adhesion, migration, and angiogenesis. In addition, several studies have also shown that CEBPA and its PAL subclasses can be modulated by various therapeutic agents, including drugs and small molecules.

One of the most promising aspects of CEBPA and its PAL subclasses is their potential as drug targets. Several studies have shown that inhibition of CEBPA or its PAL subclasses can lead to therapeutic effects in various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders. For example, several studies have shown that inhibition of CEBPA can lead to increased cancer cell proliferation and migration. In addition, inhibition of CEBPA or its PAL subclasses has also been shown to improve cardiovascular outcomes in various animal models of disease.

CEBPA-DT: A Potential Biomarker:

In addition to its potential as a drug target, CEBPA and its PAL subclasses have also been shown to be potential biomarkers for various diseases. Several studies have shown that the expression of CEBPA and its PAL subclasses can be used as biomarkers for various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders. For example, several studies have shown that increased expression of CEBPA and its PAL subclasses can be used as biomarkers for cancer. In addition, inhibition of CEBPA or its PAL subclasses has also been shown to improve diagnostic accuracy in various diseases, including cancer.

Conclusion:

CEBPA-DT is a novel protein that has been shown to be expressed in endothelial cells and to play a critical role in the regulation of cell signaling pathways. Its function as a potential drug target and biomarker for various diseases makes it an attractive target for further research and development. Further studies are needed to fully understand the role of CEBPA-DT in various physiological processes and to

Protein Name: CEBPA Divergent Transcript

The "CEBPA-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEBPA-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets